First the calendar. You have the dates right, ASCO GI runs January 21 to 23, 2027, at Moscone West in San Francisco. (ASCO GI 2027, Jan 21-23, San Francisco) And your read on the embargo rhythm is correct, the abstract publishes a few days ahead of the live session, which is the moment the pre-meeting embargo lifts and we finally see numbers that, by then, are already old.
Now the distinction you drew, which is the valuable one, An ASCO abstract is a snapshot frozen at a submission cutoff, and for this meeting that cutoff is roughly late September. So what we read in January is a photograph of how CLOVER looked in the early fall, not how it looks the day we read it. For most trials that gap is a footnote. For this one it is the whole story. CLOVER’s signal has been maturing in the direction of more responses, investigator-assessed partial responses waiting on confirmation, ctDNA deepening, the rollover arm accruing. A dataset that is still ripening does not sit still across four months. So the abstract is likely to understate where the trial actually stands by the time it is presented, because it reports the fall and the drug has kept working through the winter. You are right to look past the abstract to the near-final data that lands just after it. The abstract is the trailer. The data is the film.
The open-label observation is the one that ties it together. In principle, an open-label trial could let news flow continuously, there is no blind to lift. In practice, the company has chosen to let the conference calendar govern disclosure, which is why our knowledge has run months behind the reality the entire way. That is not a complaint, it is disciplined, you hold data for the venue that gives it the most weight. But it does mean the gap between what is known inside the company and what we outside can see has been real and persistent. Which brings us to your last point.
On Wilcoxen, you and I are reading the same tea leaves and reaching the same place. The thing that makes her signing meaningful is exactly the gap you just described. She is not reacting to the fall snapshot the rest of us will get in January. She has been inside, with current access, watching the film as it develops, and she left a secure NASDAQ role to commit on the strength of what she has seen to this minute. That is the cleanest version of an insider-conviction signal, someone with everything to lose, full and current information, and a choice to buy in anyway.
I would hold one piece of discipline on it, her knowing is not the same as our knowing, and it is a read on her confidence, not a disclosure of the numbers. But as indirect evidence goes, it is close to the best kind there is, because she is betting her career on data we will not see in full until weeks after she already acted on it. Supremely good indication is the right phrase. Well said, Ken, and I cannot wait either.